Publications by authors named "Aiva Aksentyte"
Article Synopsis
- Chronic migraine affects 2-4% of adults globally and recent advances in expensive medications have prompted a review of their clinical and cost-effectiveness.
- The study analyzed data from randomised controlled trials involving 7352 adults and compared six different medications, including calcitonin gene-related peptide monoclonal antibodies, Botox, and topiramate, against placebo.
- Results showed that calcitonin gene-related peptide monoclonal antibodies ranked highest in reducing headache days and improving quality of life, while topiramate was less effective compared to these newer treatments.
Background: Migraine is the second most common prevalent disorder worldwide and is a top cause of disability with a substantial economic burden. Many preventive migraine medications have notable side effects that affect different body organs.
Method: We systematically searched for published randomised controlled trials (RCTs) using terms for migraine/headache and preventive medications.
Article Synopsis
- Chronic migraine is a severe disorder that can be managed with preventive medications, but it's unclear which one is most effective; this study uses network meta-analysis to evaluate their effectiveness.
- The analysis reviewed 12 randomized controlled trials of six medications, all of which successfully reduced headache and migraine days compared to placebo; Eptinezumab 300mg was found to be the most effective for monthly headache days, while Fremanezumab was the best for monthly migraine days.
- Despite all six medications showing benefits, the improvement in headache/migraine days was only modest, and crucial information on other common treatments was missing due to lack of suitable studies.